CN105814033B - α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法 - Google Patents

α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法 Download PDF

Info

Publication number
CN105814033B
CN105814033B CN201480067663.3A CN201480067663A CN105814033B CN 105814033 B CN105814033 B CN 105814033B CN 201480067663 A CN201480067663 A CN 201480067663A CN 105814033 B CN105814033 B CN 105814033B
Authority
CN
China
Prior art keywords
crystal
anhydrous
compound
crystalline hydrate
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480067663.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN105814033A (zh
Inventor
吴科
G·安布鲁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN105814033A publication Critical patent/CN105814033A/zh
Application granted granted Critical
Publication of CN105814033B publication Critical patent/CN105814033B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201480067663.3A 2013-12-13 2014-12-12 α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法 Expired - Fee Related CN105814033B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915575P 2013-12-13 2013-12-13
US61/915,575 2013-12-13
PCT/US2014/070156 WO2015089475A1 (en) 2013-12-13 2014-12-12 Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof

Publications (2)

Publication Number Publication Date
CN105814033A CN105814033A (zh) 2016-07-27
CN105814033B true CN105814033B (zh) 2019-10-25

Family

ID=52282957

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480067663.3A Expired - Fee Related CN105814033B (zh) 2013-12-13 2014-12-12 α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法

Country Status (16)

Country Link
US (2) US9353079B2 (enExample)
EP (1) EP3080096A1 (enExample)
JP (2) JP2016539994A (enExample)
KR (1) KR20160097310A (enExample)
CN (1) CN105814033B (enExample)
AU (1) AU2014361794B2 (enExample)
BR (1) BR112016013594A8 (enExample)
CA (1) CA2933556A1 (enExample)
CL (2) CL2016001448A1 (enExample)
IL (2) IL245917B (enExample)
MX (1) MX2016007717A (enExample)
RU (1) RU2730520C2 (enExample)
SA (1) SA516371307B1 (enExample)
SG (2) SG11201604787SA (enExample)
UA (1) UA121108C2 (enExample)
WO (1) WO2015089475A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3658149B1 (en) 2017-07-25 2021-11-10 Allergan, Inc. Solid complex comprising (z)-7-((1r,2r,3r,5s)-2-((s,e)-5-(2,5-dichlorothiophen-3-yl)-3-hydroxypent-1-en-1-yl)-3,5-dihydroxycyclopentyl)hept-5-enamide, preparation and uses thereof
WO2021152473A1 (en) * 2020-01-29 2021-08-05 Kci Licensing, Inc. Multiple fluid pathway connector with foam supports

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1999025358A1 (en) * 1997-11-19 1999-05-27 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US20020198249A1 (en) * 1992-09-21 2002-12-26 Burk Robert M. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES416865A1 (es) * 1972-07-13 1976-03-01 Pfizer Procedimiento para preparar w-pentanorprostaglandinas sus- tituidas en la posicion 15.
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2159734T3 (es) * 1995-05-18 2001-10-16 Allergan Sales Inc Derivados 2-heteroarilalquenilicos del acido ciclopentano-heptan(en)oico como agentes terapeuticos para el tratamiento de la hipertension ocular.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US20020198249A1 (en) * 1992-09-21 2002-12-26 Burk Robert M. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1999025358A1 (en) * 1997-11-19 1999-05-27 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
SA516371307B1 (ar) 2018-10-04
SG11201604787SA (en) 2016-07-28
RU2730520C2 (ru) 2020-08-24
JP2016539994A (ja) 2016-12-22
UA121108C2 (uk) 2020-04-10
AU2014361794B2 (en) 2019-04-04
US20150166504A1 (en) 2015-06-18
US9353079B2 (en) 2016-05-31
KR20160097310A (ko) 2016-08-17
CL2016001448A1 (es) 2017-03-03
IL245917B (en) 2021-06-30
MX2016007717A (es) 2016-09-09
BR112016013594A8 (pt) 2020-05-19
BR112016013594A2 (enExample) 2017-08-08
US20170087163A1 (en) 2017-03-30
JP2020073513A (ja) 2020-05-14
EP3080096A1 (en) 2016-10-19
IL283810A (en) 2021-07-29
IL245917A0 (en) 2016-08-02
CA2933556A1 (en) 2015-06-18
SG10201709702UA (en) 2018-01-30
WO2015089475A1 (en) 2015-06-18
CN105814033A (zh) 2016-07-27
AU2014361794A1 (en) 2016-06-16
CL2019000471A1 (es) 2019-07-12

Similar Documents

Publication Publication Date Title
JP6916969B1 (ja) ３−（（１Ｒ，３Ｒ）−１−（２，６−ジフルオロ−４−（（１−（３−フルオロプロピル）アゼチジン−３−イル）アミノ）フェニル）−３−メチル−１，３，４，９−テトラヒドロ−２Ｈ−ピリド［３，４−ｂ］インドール−２−イル）−２，２−ジフルオロプロパン−１−オールの固体形態及び置換されたフェニル又はピリジニル部分を含む縮合三環式化合物を調製するための方法とそれらの使用方法
JP4727925B2 (ja) 統合失調症およびうつ病等の疾患を処置するためのフェノキシピペリジン
CN1303283A (zh) 噻吩基吡咯基烷氧基乙胺,它们的制备以及它们作为药物的应用
CN105814033B (zh) α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法
JP2010095550A (ja) キノリン誘導体
JP5061134B2 (ja) ２−フェニルベンゾチアゾリン誘導体またはその塩類からなるκオピオイド受容体アゴニスト
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
MX2007016179A (es) Formas cristalinas de o-desmetilvenlafaxina.
SK162795A3 (en) N-substituted azaheterocyclic carboxylic acids and esters thereof, preparation method thereof and pharmaceutical compositions containing them
TWI659041B (zh) 類固醇樣化合物之多晶型形式以及其製備方法及用途
HK1227389B (zh) α，ω二取代二羟基环戊基化合物的固体形式及其制备和使用方法
JP2000517342A (ja) 結晶性医薬品
HK1227389A1 (en) Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation and use thereof
JPH07107062B2 (ja) 化学化合物とその製法
JPH06102664B2 (ja) 局所的に有効なカルボニツクアンヒドラーゼ阻害剤としての５―カルバモイルチエノ〔２，３―ｂ〕チオフエン―２―スルホンアミド類及び製造方法
HK1227410A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
WO2019015640A1 (zh) 一种氮杂环酰胺衍生物的盐、其晶型及其制备方法和用途
US20240239791A1 (en) Processes for the synthesis of valbenazine
JPH11504616A (ja) ジベンズ［ｃｄ，ｆ］インドール誘導体
JP2025531367A (ja) Ｔｒｐｖ１アンタゴニストの結晶多形形態およびその製剤
JP2013107856A (ja) アデノシン誘導体を含有する炎症性眼疾患の治療又は予防剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1227389

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20191025

Termination date: 20211212

CF01 Termination of patent right due to non-payment of annual fee